Moss, 28 January 2026
Gentian Diagnostics ASA will host an educational webinar focused on NT-proBNP, a widely used biomarker in the diagnosis and management of heart failure.
The live webinar will take place on 25 February 2026 at 15:00 CET and will feature presentations by Peder L. Myhre, Professor of Cardiology at the University of Oslo, and Robert H. Christenson, Professor of Pathology at the University of Maryland School of Medicine.
The webinar will address current clinical use of NT-proBNP as well as biological and analytical challenges, including the impact of NT-proBNP glycosylation on assay performance and clinical interpretation.
The webinar forms part of Gentian’s ongoing scientific and educational outreach related to its NT-proBNP development program. A recording will be made available following the live event.
The webinar is hosted by Labroots and can be accessed via the following link: https://www.labroots.com/ms/webinar/glycosylation-nt-probnp-clinicians-laboratories
For further information, please contact:
Njaal Kind, CFO
njaal.kind@gentian.no
+47 919 06 525
About Gentian Diagnostics
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in vitro diagnostic reagents. Our mission is to innovate diagnostic efficiency for better treatment decisions. Gentian’s expertise and focus lie within immunoassays, specifically for infections, inflammation, kidney disease and heart failure. By converting existing and clinically relevant biomarkers to the most efficient, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian Diagnostics is headquartered in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA, and China. For more information, please visit www.gentian.com.